IGC Pharma develops AI-driven model to improve diagnosis of Alzheimer’s

IGC Pharma (IGC) announced an advancement in its Artificial Intelligence platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer’s disease and other causes of dementia. With Alzheimer’s accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease, and frontotemporal degeneration, accurate diagnosis is critical to ensuring the right treatment strategy. IGC Pharma’s AI model is designed to address these challenges by integrating vast clinical datasets and leveraging deep learning algorithms to distinguish between the different diseases that cause dementia. By reducing false negatives and misdiagnoses, the model has the potential to significantly improve early detection, ensuring patients receive the right treatment at the right time. The AI model is being trained on multi-modal clinical data from leading public research databases, including the National Alzheimer’s Coordinating Center, the Alzheimer’s Disease Neuroimaging Initiative, and the Parkinson’s Progression Markers Initiative, among others. By analyzing neuroimaging biomarkers, cognitive assessments, genetic risk factors, medical history, neurological exams, and demographic information, IGC Pharma’s AI-driven approach enables a more precise and scalable diagnostic framework. Using transformer-based neural networks, the model’s architecture is designed to process diverse patient data while compensating for missing information-delivering reliable, personalized insights across different patient populations.